Dexmedetomidine – USA

Dexmedetomidine – USA

On Jan. 22, 2019, Federal Circuit upheld (Rule 36 Judgment) a lower court ruling that Amneal’s proposed ANDA product of Precedex infringes a valid Hospira patent & remaining patents are invalid. 

Previously, on Jan 22, 2018, District court of Delaware found 3 patents invalid & infringed and remaining 1 patent valid & infringed by Amneal (reported here on this blog). Specifically, Plaintiff (Hospira) asserted claims 3 and 4 of U.S. Patent No. 8,242,158; claim 4 of U.S. Patent No. 8,338,470; claim 5 of U.S. Patent No. 8,455,527 and claim 6 of U.S. Patent No. 8,648,106. The’ 158, ‘470, and’ 106 patents each describe ready-to-use pharmaceutical compositions of dexmedetomidine disposed within a sealed glass container.  Considering all of the evidence, court concluded that defendant has proven by clear and convincing evidence that claims 3 and 4 of the ‘158 patent, claim 4 of the ‘470 patent, and claim 5 of the ‘527 patent are invalid as obvious but it has failed to provide clear and convincing evidence that claim 6 of the ‘ 106 patent is invalid. Particularly, court determined that the defendant failed to establish inherency of the “about 2%” limitation”. With respect to infringement court held that Amneal infringes the asserted claims of the patents including ’106 patent as a matter of law.

Interestingly, in another case with Defendant Fresenius Kabi (reported here on this blog), an Illinois judge reached the opposite conclusion on the same claim 6 of the ‘106 patent. The Illinois Court, citing additional evidence, concluded that the claim had inherent characteristics which lead to the finding of obviousness.

Leave a Reply

Leave a Reply

Your email address will not be published.

Disclaimer
All content provided on this blog is for informational purposes only. By using the blog, you agree that the information on this blog does not constitute legal or other professional advice on author's or on his company's behalf.

Copyrights 2022 Pharma IP Circle. All Rights Reserved